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Background. Rectal tumourmanagement depends highly on locoregional extension. Rectal endoscopic ultrasound (ERUS) is a good
alternative to computed tomography andmagnetic resonance imaging. However, inHungary only a small amount of rectal tumours
is examined with ERUS. Methods. Our retrospective study (2006–2012) evaluates the diagnostic accuracy of ERUS and compares
the results, the first data from Central Europe, with those from Western Europe. The effect of neoadjuvant therapy, rectal probe
type, and investigator’s experience were also assessed. Results. 311 of the 647 ERUS assessed locoregional extension. Histological
comparison was available in 177 cases: 67 patients underwent surgery alone; 110 received neoadjuvant chemoradiotherapy (CRT);
ERUSprecededCRT in 77 and followed it in 33 patients. T-stagingwas accurate in 72%of primarily operated patients. N-stagingwas
less accurate (62%). CRT impaired staging accuracy (64% and 59% for T- and N-staging). Rigid probes were more accurate (79%).
At least 30 examinations are needed to master the technique. Conclusions. The sensitivity of ERUS complies with the literature.
ERUS is easy to learn and more accurate in early stages but unnecessary for restaging after CRT. Staging accuracy is similar in
Western and Central Europe, although the number of examinations should be increased.
1. Background
Rectal tumours require special diagnostic and therapeutic
approach due to their location. This is partly attributable to
the way they spread: they are characterised by transmural
invasion; thus they infiltrate adjacent tissues in a relatively
short time.The vicinity of the anal sphincter poses a problem,
as the maintenance of continence should also be attempted
besides the oncological principles. Due to their anatomy,
rectal tumoursmaymetastasise in several anatomical regions,
and distantmetastasesmight be formed in the liver and in the
lungs via the vena cava system.
There are several therapeutic options available: endo-
scopic or surgical resection as well as irradiation and
chemotherapy. A precise knowledge of the TNM-stage is
crucial for choosing the adequate treatment option [1]. Hep-
atic and pulmonary metastases can be effectively identified
with CT, but it is not appropriate for the evaluation of the
tumour extension and the regional lymph nodes [2]. For
these two complementary modalities are available: MRI and
ERUS. Although MRI might be an ideal choice with its high
accuracy, its limited availability prevents it from becoming a
routine procedure in the clinical practice except for Western
Europe [3–6]. Thus, in other parts of the world, including
Hungary, ERUS remains the primary diagnostic tool for
determining the depth invasion of the tumour [6–8]. This
is due to the fact that ERUS is well tolerated by patients; it
is simple, quick, easy to learn, accurate, and cost effective
[9, 10]. The aim of this study was to assess the accuracy of
ERUS in patients with rectal carcinoma in the routine clinical
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practice based on the data collected from a single centre in
Hungary and to compare it with data fromWestern European
countries.
2. Methods
The first endorectal ultrasound for tumour staging was
performed on November 15, 2006, at our university cen-
ter. In the present study, ERUS examinations aiming to
determine the depth infiltration and lymph node metas-
tases of rectal tumours were evaluated retrospectively. The
data were obtained from the period between November 15,
2006, and December 31, 2012. Before the examinations, full-
bowel preparation (polyethylene glycol-electrolyte solution
or sodium picosulfate) was applied to empty the rectum.
Endorectal ultrasounds were performed with a rigid rec-
toscope (Hitachi Aloka ASU-67 with mechanical radial
(360∘) transducer using 7.5–10MHz frequency range) or a
flexible echoendoscope. Two flexible probes were available:
Olympus GF-UE 160 and Fujinon EG-530 UR (electronic
radial (360∘) probes, with 4 frequency options in the 5–10
and 5–12MHz frequency range). ERUS examinations were
carried out by two gastroenterologists who gained expertise
in both endoscopic techniques and ultrasound diagnostics.
In the initial period, several experts familiar with ultrasound
diagnostics were present during the examinations, and the
images were interpreted based on their common consensus.
Later, the examiner interpreted the endosonographic image
alone. Staging was based on the TNM classification. The
endosonographically defined clinical stagewas indicatedwith
uT and uN. According to the clinical staging results, the
tumorous lesionwas removed surgically or endoscopically, or
neoadjuvant therapy was first administered, according to the
applicable oncological protocols. Besides the ERUS for initial
staging, a second one was carried out on some of the patients
who received neoadjuvant treatment, aiming to determine
the current stage before surgery, to estimate downstaging,
if there had been any. The final stage was determined after
the pathological procession of the surgical specimens (pT,
pN and ypT, ypN in case of patients who received neoad-
juvant treatment). The required data were collected from
MedSolution patient recording system. Only those patients
were involved in our analysis whose histopathological results
with the final tumour stage were available. Patients were
divided into three groups depending on the neoadjuvant
treatment. Patients in the first group underwent surgical
intervention without previous oncological treatment. ERUS
was performed after chemoradiotherapy on patients of the
second group. In the third group, ERUS was performed
first, but CRT was also necessary before surgery, because
of the advanced stage of the disease. In the latter case,
the later date of the histopathological findings, as well as
the effect of CRT on staging, had also been taken into
consideration in the evaluation of the accuracy.The accuracy
of endorectal ultrasonography was evaluated by comparing
uT, uN and yuT, yuN stages with the final pT, pN and ypT,
ypN stages. The measure of correspondence was determined
and was also characterised by Cohen’s kappa coefficient.
The overstaging and understaging rates were investigated
as well. The sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) of ERUS were
calculated for each tumour stage. Evaluating the N-staging
accuracy, the ability of ERUS to recognise metastatic lymph
nodes was investigated; therefore no difference was made
between N1- and N2-stages. The operator-dependency of
ERUS was also investigated as well as the extent to which
the experience of the endosonographer (learning curve)
affects the accuracy. The learning curve was determined on
the group that did not receive neoadjuvant treatment. The
correctness of the endosonographic diagnoses from a single
examiner was also evaluated in correlation with the number
of examinations performed. Our results were compared to
the largest multicentre, prospective, countrywide, and real-
life study conducted by Marusch et al. in Germany [11], as
a representative of the staging accuracy of ERUS in Western
Europe.
3. Results
In the six-year study period, a total of 647 endorectal ultra-
sounds were performed. 311 of the examinations aimed to
determine the locoregional extension of the tumour. 30
examinations failed due to inaccessible lesions (significant
narrowing of the lumen or lesion located above the distance
accessible with the probe), probe failure, or inadequate bowel
preparation. Histopathological results with the final tumour
stage were available in only 177 cases. In the other cases,
the surgery and pathological procession was performed in
another institution, and only the staging with ERUS was
performed in our institution. 67 of the 177 patients under-
went surgery without previous chemoirradiation within an
average interval of 24 days after the endosonographical
staging (Group I); the other 110 patients received oncological
treatment prior to the surgery: ERUS was performed before
the neoadjuvant treatment in 77 patients (Group III) and after
that in 33 patients (Group II).
3.1. Accuracy of T-Staging. In terms of the T-staging accuracy,
a significant difference was noted between the three groups.
The correspondence was highest (72%) in the group that did
not receive CRT, with Cohen’s kappa coefficient of 0.482,
indicative of a moderate correspondence. 11 cases (16%) were
overestimated and 8 were underestimated (12%) (Table 1).
In this patient group, the pathological examination of the
resected tissue revealed T3 stage in 12 patients; thus primary
oncological treatment would have been necessary according
to the current therapeutic protocols. ERUS reported uT3
stage in 7 of these cases and uT2N1 in one of the cases;
therefore understaging led to inappropriate treatment in only
4 patients. It should be noted, however, that in these four
cases the time interval between the endosonography and the
surgery was longer (an average of 38 days).
The accuracy rate of ERUS was lower after neoadjuvant
treatment (64%). In this group, overstaging was more fre-
quent (27%) and 3 cases were understaged (9%). ERUS before
CRT complied with the histopathological results in only 34%
of the cases, accompanied by Cohen’s kappa coefficient of
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correspondence 72% 64% 34%
Kappa coefficient 0.482 0.390 0.019
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Figure 1: Accuracy of T-staging in each patient group.
0.019 indicating poor correspondence. The overstaging rate
was prominently high in this group (57%) (Figure 1).
In the majority of patients who did not receive CRT,
early stage tumours were detected (the histopathological
examination revealed pT1 in 61%, pT2 in 16%, and pT3 in
18% of the cases). At least moderate correspondence could
be observed for each tumour category; the correspondence
was highest for T3 tumours (𝜅 = 0.606). Three-quarters of
pT1 and pT2 tumours were identified correctly with ERUS
(with a sensitivity of 75% and 73%, resp.), but, in case of
T3 tumours, the sensitivity was only 58%. Unlike the high
positive predictive values for T1 and T3 tumours, only 42%
of the endosonographically defined T2 tumours were proved
to be T2. The majority of uT2 cases were overestimated, as
ERUS reported T2 instead of T1 (Table 2).
In accordance with the current protocols, the majority
of the patients who received neoadjuvant treatment had
T3 tumours. In two cases, the pathological results showed
complete regression; no residual tumour tissuewas detectable
in the resected tissue. None of these could be identified
endosonographically; the lesions were overestimated. It has
been proven that the ERUS results of patients who received
oncological treatment shifted towards overstaging compared
to those who underwent surgery as a primary intervention
Table 2: Accuracy of ERUS for each T stage without neoadjuvant
therapy, throughout the whole study period (𝑛 = 67).
uT1 uT2 uT3
uT-pT correspondence
(kappa coefficient) 0.465 0.411 0.606
Sensitivity 75% 73% 58%
Specificity 74% 80% 96%
PPV 85% 42% 78%
NPV 61% 94% 91%
Table 3: Accuracy of ERUS for each T stage after neoadjuvant
therapy (𝑛 = 33).
yuT1 yuT2 yuT3
uT-pT correspondence
(kappa coefficient) 0.218 0.415 0.525
Sensitivity 20% 67% 82%
Specificity 96% 83% 63%
PPV 50% 60% 70%
NPV 87% 87% 77%
(27% and 57% of the lesions were overstaged after and before
the neoadjuvant treatment, resp.) (Figure 1).
After neoadjuvant CRT, the level of correspondence was
lower for all of the T1-T3 stages. Correspondence was highest
(𝜅 = 0.525) for T3 tumours, 70% of the lesions described
as yuT3 proved to be actually ypT3, and the sensitivity was
82%. A lower level of correspondence was observed in less
advanced lesions; in T1 tumours, the sensitivity was only 20%
and the positive predictive value was 50% (Table 3).
3.2. Accuracy of N-Staging. Lymph node involvement was
both reported with ERUS and mentioned in the histopatho-
logical findings in 123 patients. 29 of these patients underwent
surgery as a primary treatment (Group I); the endosono-
graphical staging preceded (Group III) and followed (Group
II) CRT in 29 and 65 cases, respectively. In Groups I and II,
the tumour stage seen with ERUS corresponded with the N-
stage in the pathological results in 62% and 59% of the cases,
respectively. This rate was significantly lower in Group III
(45%). Understaging was more frequent in the former two
categories (21% and 28%), while overstaging prevailed in the
third one (40%) (Figure 2). It could also be noted that ERUS
could more reliably recognise the absence of lymph node
metastases than their presence (Table 4).
3.3. Learning Curve. The time needed for gaining appropriate
experience was investigated in the group that did not receive
CRT; these 67 patients were divided into two groups; the 33
results of the initial period were compared to the subsequent
34 (Figure 3). The uT-pT correspondence was found to be
significantly higher in the later period than in the initial one
(𝑃 = 0.034). Furthermore, the understaging and overstaging
rates both decreased.When taking into account only the cases
from the later period, the sensitivity of ERUS reached 75% in
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Table 4: Accuracy of N-staging in each patient group.
Group I (𝑛 = 29) Group II (𝑛 = 29) Group III (𝑛 = 65)
Sensitivity 14% 11% 50%
Specificity 77% 80% 42%
PPV 17% 20% 28%
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Figure 2: Accuracy of N-staging in each patient group.
all T-stages. All of the endoscopic T3 tumours were identified
correctly (Table 5).
The learning curve of one of the examiners was deter-
mined based on 43 ERUS examinations, by comparing the
accuracy of the results divided into groups of 10 cases. The
level of correspondence was found to be significantly higher
after 30 examinations, suggesting a plateau phase or even a
further increasing tendency (Figure 4).
Our case number was insufficient for determining the
learning curve of the N-staging.
3.4. Accuracy of Rigid and Flexible Probes. Rigid and flexible
probes were compared based on their results in patients
who did not receive CRT. 29 examinations were carried out
with the rigid Aloka ASU-67 probe and 38 were carried out
with the flexible Olympus GF-UE 160, Fujinon EG-530UT,
and EG-530UR probes. The uT stage determined with the
rigid probe showed a higher rate of correspondence with
the final pT stage than the one defined with flexible probes
(79% and 66%) (Figure 5). Inaccuracy of the rigid probe
was exclusively due to overestimation, while underestimation
could also be observed with the flexible devices; moreover,
it was more frequent than overestimation. N-staging of the
rigid probe could only be evaluated in six cases; the uN-pN
stages were identical in five cases, and, in one case, the lymph
node detected with ERUS did not prove to be metastatic. In
case of the flexible devices, the results corresponded in 13 of
Table 5: Accuracy of ERUS for each T stage without neoadjuvant
therapy, in the later study period after reaching a plateau in the
learning curve (𝑛 = 34).
uT1 uT2 uT3
uT-pT correspondence (kappa coefficient) 0.643 0.519 0.821
Sensitivity 80% 83% 75%
Specificity 86% 82% 100%
PPV 89% 50% 100%



















Figure 3: The accuracy of ERUS over time.
the 23 cases; lymph node involvement was underestimated in
six cases.
4. Discussion
The overall accuracy of ERUS in determining the depth
invasion of the primary tumour (T stage) was found to
be 72% in the patient group that did not receive CRT,
with Cohen’s kappa coefficient indicating moderate cor-
respondence, which complies with the international data
[11, 12]. According to a multicenter study performed in
Germany, the overall accuracy of ERUS was determined
as 73.1% for hospitals performing >30 ERUS/year. This
rate was accomplished in our center as well. Overstaging
was the most frequent mistake in all three patient groups
(16%-27%-57%). The reason for this might be the so-called
peritumoral inflammatory reaction, which cannot be distin-
guished endosonographically from the tumour itself [13, 14].
Understaging was mainly due to microscopic tumorous infil-
tration, which is impossible to detect with endosonography.
It might as well occur in extensive tumours and when the
upper part of the lesion is inaccessible for the probe. As
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Figure 5: Accuracy of T-staging in case of flexible and rigid probes.
the depth of invasion varies throughout the longitudinal
extension of the tumour, an impairment in accuracy occurs
when the tumour tissue cannot be examined as a whole
[15, 16]. Differentiating between T1/T2 and T2/T3 tumours
can raise further problems, as the penetration through the
wall layers is often ambiguous; it might only be indicated
by the irregularity of the surface between the layers. In case
of extensive tumours, determining submucosal involvement
might as well be difficult, as it can be easily mistaken for
the widening of the muscular propria [15, 16]. Differentiating
between T2/T3 tumours plays an important role in clinical
decision-making, as the necessity of CRT depends on it. Out
of the 67 cases five pT3 lesions were underestimated (three
were reported as uT1 and two were reported as uT2); The
overall clinical stage for one of the uT2 tumours was uT2N1.
This means that, based solely on the endosonographical
staging, 94% of the patients could receive adequate therapy,
appropriate for the pathological stage. A significant variation
in sensitivity was observed between T1-T2 and T3 stages in
patients who underwent surgery without neoadjuvant CRT
(75%-73% and 58%). It is ascertainable that while ERUS is a
good diagnostic choice in case of early rectal malignancies,
MRI is recommended for staging advanced lesions, due to
its higher sensitivity [3, 17]. A significant difference was
shown in terms of all the investigated parameters between
the patient group that underwent surgery alone and the ones
that received oncological treatment. This might be due to the
effect of chemoirradiation on tissues: inflammation, fibrosis,
and necrosis occurring as a consequence of the treatment
can hardly be differentiated endosonographically from the
tumorous tissue [18, 19]. The overstaging rate was 27–57%
for Groups II and III, respectively. Taking into account the
lower positive predictive value of themethod and the fact that
the level of yuT-ypT correspondence is only sufficient (𝜅 =
0.390), it can be stated that ERUS itself is not appropriate
for restaging after CRT. The yuT stage is not acceptable for
evaluating the effectiveness of neoadjuvant therapy. ERUS
performed prior to CRT reported a more advanced lesion
than the final stage in a great percentage of the cases. Effective
neoadjuvant treatment leads to a decrease in the tumour
stage, which results in a discrepancy in the level of uT-pT
correspondence and the overstaging rate compared to the
patients who received no CRT [11].
The accuracy of N-staging was only 62%, and neither
the sensitivity nor the positive predictive value of ERUS is
acceptable.Therefore, it is inappropriate for the identification
of metastatic lymph nodes. Currently, this is the greatest
limiting factor of ERUS in rectal cancer staging. The method
can only draw conclusions from the morphological features
of lymph nodes to decide whether they are metastatic or
not; however, there is no consensus about the staging criteria
to be used [14, 20]. Most questions are being raised about
the determination of the lymph node size that should be
considered to be pathologic, as normal sized lymph nodes
may also contain metastatic deposits, and, on the other hand,
lymph node enlargement is not necessarily due tometastasis-
formation. The facts that the evaluation of the perirectal fat
is of limited availability on higher frequencies and that only
lymph nodes adjacent to the rectum can be investigated with
ERUS raise further problems [16].
Another limiting factor of ERUS is its operator-depend-
ency. At the same time, this also means that in the hands
of an experienced diagnostician it is a reliable method
providing a great amount of information [21, 22]. According
to our results, the learning curve is relatively short; after 30
examinations it is possible to evaluate the depth invasion
of rectal cancers with confidence. Above this case load, the
staging accuracy reached a significantly higher level (from
64% to 79%), which complies with the international statistics
[11, 23]. Moreover, in the later period, after reaching the
plateau phase of the learning curve, the sensitivity of ERUS
for each tumour stage exceeded the results reported from
a multicentre study from Germany (80%-83%-75% versus
58%-64%-71%) [11]. The reason for the better results in the
initial period (first 10 examinations) after the introduction of
ERUS to our institution might be the fact that several experts
were present at the examinations and the endosonographical
images were interpreted based on a common consensus.
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This could be a promising possibility for increasing the
accuracy of ERUS in case of investigators without sufficient
experience. Inevitably, regular practice is also crucial for
high-level staging.
Flexible probes have several advantages over rigid ones:
they are easier to manoeuvre with; due to their smaller
diameter they are able to traverse a narrower lumen and
to access higher locations than the rigid ones. Besides, a
great advantage of flexible devices is the possibility of visual
control, which is not availablewith rigid (“blind”) probes [15].
However, our results seem to support the fact that they stay
behind the rigid probes in terms of both T- and N-staging.
Thus, rigid probes are still favourable over flexible ones, due
to their lower costs and higher accuracy [24].
5. Conclusions
In the present study, ERUS was found to be of high accuracy
in rectal tumour staging in accordance with the literature. No
previous study has collected such extensive data on the accu-
racy of ERUS in the Central and Eastern European region.
There is no significant difference between the accuracy of
the modality in Central and Western European countries.
After the relatively short learning curve, our results were
even above the Western European standards, although they
only represent the performance of a single centre not a
countrywide analysis. ERUS is the method of choice for
determining the depth invasion of the primary lesion in early
malignancies, due to its simplicity, efficacy, low costs, and
the fact that it is relatively well tolerated. After CRT, the
inflammatory tissue reaction decreases its efficiency; thus
it is not recommended for the evaluation of downstaging.
However, the accuracy of ERUS might be similar in Central
and Western Europe; one difference still remains: the extent
of awareness of the modality and its availability. Although
ERUS is becoming more and more widespread in Hungary,
it is rarely part of the routine clinical practice. According
to a questionnaire among 50 young surgeons in 2013, 51%
of surgeons found ERUS the most accurate tool in terms of
determining locoregional invasion, and only 33% of them
uses it for staging; thus it is used in less than 10% of rectal can-
cers. Although some administration and organisation might
be required from the attending physician, ERUS is utterly
recommended for the adequate treatment of all patients with






MRI: Magnetic resonance imaging.
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